Keynote Financial Services’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.28M Sell
94,489
-910
-1% -$23.8K 1.07% 22
2026
Q1
$2.68M Sell
95,399
-2,915
-3% -$77.6K 1.42% 16
2025
Q4
$2.45M Sell
98,314
-807
-0.8% -$20.4K 1.37% 14
2025
Q3
$2.53M Buy
99,121
+1,897
+2% +$46.8K 1.52% 11
2025
Q2
$2.36M Buy
97,224
+7,877
+9% +$184K 1.58% 11
2025
Q1
$2.26M Buy
89,347
+4,353
+5% +$114K 1.62% 12
2024
Q4
$2.25M Buy
84,994
+16,710
+24% +$453K 1.73% 10
2024
Q3
$1.98M Buy
68,284
+2,607
+4% +$76K 1.51% 11
2024
Q2
$1.84M Buy
65,677
+2,064
+3% +$56.8K 1.54% 13
2024
Q1
$1.77M Buy
+63,613
New +$1.77M 1.48% 13

Other funds holding PFE

Keynote Financial Services's PFE Position: Q2 2026 in Review

Keynote Financial Services reduced its Pfizer (PFE) stake by 0.95% in Q2 2026, selling an estimated $23.8K and leaving 94,489 shares worth $2.28M. The position accounts for 1.07% of the portfolio, ranked #22.

Keynote Financial Services first reported a position in PFE in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.68M in Q1 2026. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Keynote Financial Services held 94,489 shares of Pfizer worth $2.28M as of Q2 2026.
  • Keynote Financial Services sold 910 Pfizer shares in Q2 2026, an estimated $23.8K.
  • Pfizer made up 1.07% of Keynote Financial Services's portfolio in Q2 2026, its #22 holding.
  • Keynote Financial Services first reported a position in Pfizer in Q1 2024 and has held it in 10 quarters since.
  • Keynote Financial Services's Pfizer position peaked at $2.68M in Q1 2026.
  • 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Keynote Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.